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Propranolol has been effective in suppressing ventricular
arrhythmias in up to 70% of patients in some series;
however, a wide range of concentrations was required
to produce this degree of efficacy. In one series, 40% of
responders required high serum concentrations (> 500
ng/ml) in excess of those required for physiologic beta-
receptor blockade (25 to 150 ng/ml), To assess the rel-
ative contribution of high concentration electrophysio-
logic effects to antiarrhythmic efficacy the results of pro-
grammed electrical stimulation were compared at high
and low (beta-blocking) concentrations in 28 patients
with inducible sustained ventricular tachycardia. Pro-
pranolol was given as a series of loading and maintenance
infusions producing first a mean concentration of 130 ±
72 ng/ml (beta- blocking) and then a mean concentration
of 743 ± 523 ng/ml (high). Beta-blockade was assessed
by the percent reduction in exercise-induced tachycar-
Propranolol has been shown to be effective in suppressing
ventricular arrhythmias in man ( 1-4). In a study of Woosley
et al. (4) chronic ventricular arrhythmias were suppressed
by propranolol in 70% of patients; however, 40% of re-
sponders required propranolol concentrations of 150 to 1,000
ng/ml for efficacy. These high concentrations are in excess
of those required for beta-adrenoceptor blockade (25 to ISO
ng/ml) (5- 9) . Other studies have shown that high concen-
trations of propranolol have electrophysiologic effects that
are not mediated through the beta-adrenoceptor (10 ,11).
The se data suggest that high concentration electrophysio-
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dia . Near maximal beta-blockade was achieved by a con-
centration of 150 ng/ml.
At a low concentration, 6 of 28 patients had a re-
sponse to propranolol (complete in 5 and partial in 1).
At a high concentration, one additional patient had a
complete response while three had a partial antiarrhyth-
mic response. At high concentrations of propranolol there
was a significant shortening of the QTc interval relative
to that seen during the low dose infusion. No other sig·
nificant electrophysiologic changes occurred at high ver-
sus low concentration. In summary, an antiarrhythmic
response to propranolol occurs most frequently at a beta-
blocking concentration. High concentration electro-
physiologic effects occur and these appear to contribute
to antiarrhythmic efficacy in some patients.
(J Am Coil Cardio1 1986;8:959-65)
logic effects may contribute to antiarrhythmic efficacy . The
relative efficacies of low and high concentrations of pro-
pranolol in suppressing inducible ventricular tachyarrhyth-
mias have not been systematically evaluated. Therefore, the
safety, efficacy and electrophysiologic actions of high and
low concentrations of propranolol were evaluated in patients
with inducible sustained ventricular tachycardia .
Methods
This study was designed to assess the relations among
propranolol concentration , extent of beta-adrenoceptor
blockade , electrophysiologic effects and antiarrhythmic ef-
ficacy. In addition, the abilit y of an antiarrhythmic response
to intravenous propranolol to predi ct a similar response to
oral therapy was assessed.
Study patients. Patients undergoing clinically indicated,
antiarrhythmic drug -free, transvenous catheter electrophys-
iologic testing were candidates for this stud y if sustained
unimorphic ventricular tachycardia was reproducibly in-
ducible (12). Patients were excluded from this study if
congestive heart failure (New York Heart Association class
11I-IV), insulin-dependent diabetes mellitus or chronic ob-
0735-1097/86/$3.50
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structive pulmonary disease was present. All patients gave
written informed consent and this study was approved by
our institution's Ethical Review Board.
Twenty-eight patients with inducible, unimorphic, sus-
tained ventricular tachycardia were studied (Table I). Their
mean age was 58 ± 13 years (range 27 to 77). Eighteen
of these had spontaneous sustained ventricular tachycardia,
one had ventricular fibrillation, six had nonsustained ven-
tricular tachycardia and a history of recurrent syncope and
three presented with syncope of obscure origin. Twenty-
one of the 28 patients had ischemic heart disease, 2 had
right ventricular dysplasia, I had Wolff-Parkinson-White
syndrome and ventricular tachycardia and 4 had no known
structural heart disease. The mean global ejection fraction
of the study group, as assessedby radionuclide angiography,
was 45 ± 13%. Ventricular tachycardia induction in these
patients had been reproducible on at least two separate oc-
casions. Twenty-five of the 28 patients were drug resistant
and had been unsuccessfully treated with a mean of 5 ± 3
antiarrhythmic medications including 1.3 ± I investiga-
tional drugs. None of the patients had evidence of active
Table I. Individual Patient Characteristics (n == 28)
Age (yr) Cardiac Ejection
Case & Sex Presentation Diagnosis Fraction (%)
\( R) 52 M Sust VT CAD 28
2 48 M Sust VT CAD 31
3 54 M VT + syncope None 35
4 28 M Sust VT RVdys 59
5 27 M Sust VT RVdys
6 67 F VT + syncope CAD 30
7 59 M Sust VT CAD 31
8 17M VT + syncope CAD 59
9(R) 8 1 M Sust VT CAD
10 64F Sust VT CAD 46
II(P) 74 F Syncope CAD
12 70 M Sust VT CAD
13(P) 55 M VT + syncope CAD 48
14(R) 45 M Sust VT CAD 70
15 67 M Syst VT CAD 40
16(R) 58 M Sust VT CAD 57
17 64M VF CAD 63
18 50 M Sust VT CAD 32
19 60 F VT + syncope CAD 53
20(P) 64 M Sust VT CAD 29
2 1 58 F Sust VT CAD 38
22 54 M Sust VT None 44
23(R) 66 F VT + syncope CAD 52
24 52 M Sust VT CAD 31
25(R) 6 1 F Sust VT None 59
26(P) 63 M Sust VT CAD 31
27 44M Syncope None 61
28 50 M Syncope VT + WPW 70
CAD = coronary artery disease; P = patient withh partial response;
R = patient with complete response to propranolol; RVdys = right ven-
tricular dysplasia; Sust VT = sustained ventricular tachycardia; VF =
ventricular fibrillation; VT = ventricular tachycardia; WPW = Wolff-
Parkinson-White syndrome.
ischemia and they did not develop chest pain during pacing
or exercise testing.
Study design. After withdrawal of all antiarrhythmic
medications for at least four half-lives, programmed elec-
trical stimulation studies were performed (baseline). Pro-
pranolol was then given as a series of loading and main-
tenanceinfusions designed to produce two distinctand stable
serum concentrations. The first loading infusion of I mg/min
for 20 minutes was followed by a maintenance infusion of
0. 1 mg/min; the second loading infusion of 3 mg/min for
25 minutes was followed by a maintenance infusion of 0.6
rug/min. The first loading and maintenance infusions were
designedto achieveserumpropranolol concentrationsof 150
ng/rnl, Electrophysiologic studies were not begun until 20
minutes after the start of the maintenance infusions. If ven-
tricular tachycardia continued to be inducible at the low
serum concentration, the second series of infusions was
given to achieve concentrations approximating 500 ng/ml
and electrophysiologic studies were repeated. Heart rate,
blood pressure and symptomatic state were evaluated every
5 minutes during the propranolol infusions. Serum samples
for propranolol were obtained just before and after electro-
physiologic testing at each concentration level.
Patients responding to intravenous propranolol received
oral propranolol therapy in a dosage duplicating the serum
concentrations found to be effective during the intravenous
study. Patients responding to oral propranolol were dis-
charged on this therapy and followed-up monthly with clin-
ical assessment and 24 hour ambulatory monitoring ex-
amination.
Beta-adrenoceptor blockade: concentration-response
relations. The extent of beta-adrenoceptor blockade was
measured as a percent reduction in maximal exercise heart
rate relative to that achieved in a drug-free state (13-15)
during a symptom-limited exercise test using supine bicycle
ergometry. These data were pooled to examine the relation
between drug concentration and extent of beta-adrenoceptor
receptor blockade. The percent reduction in maximal heart
rate was plotted against the logarithm of concentration and
fitted to fi ve mathematical models: linear, exponential , power
series, Em•x and sigmoid Em., using the NONLIN curve
fitting program (16). If the data were best fit by an Em.,
model then the concentration producing 50 and 90%
suppression (ED5(), ED90) of exercise-induced maximal heart
rate was calculated.
EIectrophysioIogic studies. Programmed electrical
stimulation techniques in this study involved the introduc-
tion of up to three right ventricular extrastimuli (10 times
late diastolic pacing threshold; 2 ms pulse width) during
ventricular pacing at cycle lengths of 600, 500 and 400 ms.
When sustained ventricular tachycardia was not induced
with ventricular extrastimulation, ventricular burst pacing
(4 and 12 stimuli) at cycle lengths from 300 down to 240
ms in steps of 10 ms was applied. Sustained ventricular
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Figure 1. The extent of beta-adrenoceptor blockade was mea-
sured as percent reduction in maximal exercise-induced heart rate
during a symptom-limited exerci se test. Individual data are pooled
to examine the relation between drug concentration and extent of
beta-adrenoceptor blockade. These data were best fit by a sigmoid
Emax model with an r value of 0.57 and an EDsoof 35 ng/ml. The
arrows show the mean concentrations of propranolol achieved with
the low and high dose infusions . EDso = concentration producing
50% reduction of maximal heart rate.
trations associated with complete and partial response for
each patient are presented in Table 2. Therefore, of the IO
patients demonstrating a partial or complete antiarrhythmic
response to propranolol, 6 responded at a beta-blocking
concentration, whereas 4 required a higher concentration.
Clinical criteria were examinedfor their predictive value
with respect to antiarrhythmic response. The presence of
exercise-induced ventricular tachycardia did not predict
whether a patient would or would not respond to propranolol
by suppression of inducible ventricular tachycardia. Of the
six patients having a complete response to propranolol, one
had exercise-induced tachycardia. Of the 22 nonresponding
patients, 5 had exercise-induced ventricular tachycardia. The
presence of sinus tachycardia at rest did predict antiarrhyth-
mic response. Three of the six patients responding to pro-
pranolol had a sinus tachycardia (sinus cycle length < 600
ms) at rest , while this characteristic was seen in only I of
22 nonresponders (p < 0 .05 , K). The mode of initiation
of the tachycardia did not significantly predict response to
propranolol. Of the six responders, one had ventricular
tachycardia induced by burst pacing while five had tachy-
cardia induced by conventional critically timed extrastimuli.
Of the 22 nonresponding patients, none had ventricular
tachycardia induced by burst pacing. The rate or configu-
ration of the induced tachycardia was not different in re-
sponding or nonresponding patients.
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Results
Concentration-dependent beta-adrenoceptor block-
ade. The first maintenance infusion of propranolol produced
a mean concentration of 130 ± 72 ng/ml (range 32 to 285);
the second series of infusions produced a mean concentra-
tion of 743 ± 523 ng/ml (range 229 to 1,625). None of the
patients developed hypotension or hemodynamic compro-
mise. The concentration-dependent change in percent re-
duction in exercise tachycardia was best fit by the sigmoid
Emax model with a resultant correlation coefficient of 0.57.
The regression coefficients for the other models were as
follows : linear, r = 0.48; logarithmic. r = 0 .54; Emax ,
r = 0.48; exponential, r = 0.52; polynomial r = 0.55.
The ED50 was found to be 35 ng/ml. Using this model, near-
maximal beta-adrenoceptor blockade (Emax) occurred at a
concentration of ISO ng/ml (Fig . I).
Concentration-dependent antiarrhythmic efficiency.
Complete suppression of inducible ventricular tachycardia
occurred in 6 of the 28 patients during propranolol treatment:
in 5 during the low dose infusion and in I during the high
dose infusion (Fig. 2). Five of these six patients had isch-
emic heart disease. Four additional patients had a partial
antiarrhythmic response as previously defined: one at a low
and three at a high propranolol concentration. The concen-
tachycardia was defined as that which lasted 30 seconds or
produced hemodynamic compromise requiring immediate
termination by transthoracic cardioversion or ventricular
pacing. A complete antiarrhythmic response was defined as
failure of this induction protocol to produce five or more
nonstimulated consecutive ventricular depolarizations at a
cycle length of less than 500 ms. A partial antiarrhythmic
response was defined as the induction of ventricular tachy-
cardia with three extrastimuli when only one or two ex-
trastimuli had been sufficient at baseline.
The following PR, QRS, QT and RR intervals were re-
corded at baseline and during propranolol treatment. The
rate-corrected QT (QTc) interval was calculated from the
formula QTc = QTrVRR. The ventricular effective re-
fractory period was defined as the longest extrastimulus
coupling interval that failed to produce a propagated re-
sponse. The ventricular effective refractory period was as-
sessed at ventricular pacing cycle lengths of 600, 500 and
400 ms. If ventricular tachycardia was inducible, its rate
and configuration were assessed.
Serum propranolol. Serum samples were assayed for
propranolol using a high performance liquid chromatogra-
phy method.
Statistics. Analysis of variance was used to assess the
significance of concentration-dependent changes in electro-
physiologic variables during the propranolol infusions . The
null hypothesis was rejected at a probability of less than
0 .05 . Continuous data are presented as mean ± SO.
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Figure 2. The cumulative proportion of patients
responding to propranolol is related to propranolol
concentration. The six patients with a complete re-
sponse are illustrated as the solid circles, while the
four patients with a partial response are shown as
open squares.
Table 2. Results of Programmed Electrical Stimulation and Propranolol Serum Concentrations
for Individual Patients
Inducibility Serum Levels (ng/ml)
Case Baseline Low High Oral Low High Oral
I(R) S4 NI S3 123 140
2 S4 S4 S4 138 860
3 S4 S4 S4 83 388
4 S3 S3 S2 272 917
5 S4 S3 S4 123 750
6 S3 S3 S3 100 474
7 S3 S2 S, 104 814
8 S3 S3 S3 243 1,254
9(R) S4 NI 139
10 S3 S3 S, 232 491
11(P) S3 S3 S4 366 423
12 S3 S, S3 32 194
13(P) S3 S3 S4 48 227
14(R) S4 NI NI 67 46
15 S4 S4 S3 144 754
16(R) S4 NI NI 41 NO 52
17 S4 S4 S4 131 702
18 S4 S4 S4 51 339
19 S4 S4 S4 78 578
20(P) S3 S3 S4 47 264
21 S4 S4
22 S4 S4 S4 197 423
23(R) S2 S4 NI NI 184 441 1,250
24 S3 S3 S3 288 1,625
25(R) Burst NI NI 98 118
26(P) S, S4 S3 124 622
27 S4 S3 S3 71 450
28 S4 S3 S4 66 332
NO not done; NI noninducible; P = patients with partial response; R patients with complete
response to propranolol; S3 = ventriculartachycardia inducible with two extrastimuli; S4 = ventriculartachy-
cardia inducible with three extrastimuli; - = not available.
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Table 3. Electrophysiologic Effects of Low and High
Concentration Propranolol
Parameter (x ± SO)
Propranolol Propranolol
Baseline Low High
PR interval 155 ± 28 171 ± 31 175 ± 39
QRS duration 106 ± 26 110 ± 27 112 ± 25
QTc interval 453 ± 30 433 ± 34 423 ± 37*
RR interval 736 ± 168 878 ± 190 923 ± 150
VT cycle length 250 ± 42 252 ± 38 262 ± 51
Ventricular effective refractory
period (ms)
S2
600 253 ± 27 258 ± 22 257 ± 25
500 239 ± 24 249 ± 21 249 ± 21
400 220 ± 20 230 ± 22 235 ± 24
S3
600 188 ± 15 216 ± 18 212 ± 22
500 184 ± 20 205 ± 26 204 ± 44
400 172 ± 24 188 ± 24 186 ± 30
Electrophysiologic effects athigh and low concentrations ofpropranolol
are compared with those seen at baseline by analysis of variance. * A
change at high concentration significantly different from than that seen at
low concentration. S2 and S3 = application of one or two extrastimuli,
respectively; VT = ventricular tachycardia.
Concentration-dependent electrophysiologic changes.
Table 3 reviews the electrophysiologic effects seen at low
and high concentrations. Low concentration propranolol
produced a prolongation in PR interval and sinuscycle length
with no further increase in these variables at high concen-
+40
tration. Neither low nor high concentrations of propranolol
alteredthe ventricularrefractorinessof the 82 extrastimulus,
but both significantly increased the ventriculareffective re-
fractory period of 83 • Neither low nor high concentrations
altered ventricular tachycardia cycle length.
High propranolol concentrations produced significant
shortening of the QTc interval relative to the low dose in-
fusion (433 :±: 34 ms at low concentration compared with
423 :±: 37 ms at high concentration (p < 0.05 by two-way
analysis of variance) (Fig. 3). No other differences were
seen when comparing electrophysiologic actions of low and
high concentrations. No singleelectrophysiologic responses
discriminated between patients who would or would not
respond to propranolol.
Long-term oral treatment. Five of the six patients re-
sponding to intravenous propranolol consented to a repeat
electrophysiologic studyduringoral therapyat matchedcon-
centrations. Antiarrhythmic response during oral propran-
olol treatmentwas seen in four of the fivepatientsevaluated.
The patient with discrepant oral and intravenous responses
had comparable propranolol concentrations during the two
studies (140 ng/ml with oral propranolol, 123 ng/ml during
intravenous propranolol). During 16 :±: 9 monthsof follow-
up one patient died of a cerebrovascular accident at 18
months. Onepatienthad recurrentsyncopeand nonsustained
ventricular tachycardia requiring a change in therapy after
6 months. The patient discharged on high dose propranolol
therapy developeddebilitatingdepression and lethargy after
2 weeks of follow-up. The remaining three patients are
arrhythmia- and symptom-free.
--------
o
Figure 3. Individual patient data (n =
21) relating thechange incorrected QTin-
terval (QTc) from baseline to propranolol
concentration.
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Discussion
Antiarrhythmic efficacy. Ventricular tachyarrhythmias
are frequently the common final pathway of sudden cardiac
death (17). The ability of propranolol to prevent sudden
death after myocardial infarction (18) may relate to a direct
antiarrhythmic effect (electrophysiologically mediated) or
propranolol may alter a number of antecedent pathologic
processes that could provoke ventricular tachyarrhythmias
(an example is ischemia). Both beta-adrenoceptor blocking
properties and non-beta-adrenoceptor-mediated actions of
propranolol have been proposed to contribute to its antiar-
rhythmic (19,20) and myocardial protective actions (21,22).
The antiarrhythmic activity of propranolol may be due to
blockade of adrenergic involvement in the genesis of ven-
tricular tachyarrhythmias. However, non-beta-adrenocep-
tor-mediated effects of high concentrations of propranolol
may be necessary for antiarrhythmic activity in some pa-
tients (4).
The present study indicates that propranolol has antiar-
rhythmic effects, as assessed by complete suppression of
ventricular tachycardia induction in 6 of 28 patients. High
concentrations of propranolol provided additional antiar-
rhythmic efficacy over that seen with low concentrations
(complete in one patient and partial in three). The antiar-
rhythmic activity of propranolol appears to depend predom-
inantly on its beta-adrenoceptor blocking properties; how-
ever, high concentrationeffects are necessary in some patients.
Suppression of inducible ventricular tachycardia with pro-
pranolol was seen most frequently in patients with sinus
tachycardia at rest. This feature may be a marker of ven-
tricular tachyarrhythmias with mechanisms dependent on
adrenergic stimulation.
High concentration effects. The frequency with which
propranolol was effective in the present study was substan-
tially less than that reported by Woosley et al. (4). In that
study approximately 70% of patients responded while only
21% responded in our study. While 40% of responders
required a high concentration of propranolol for antiarrhyth-
mic efficacy in the study of Woosley et al. (4), only 16%
of responders in this study required a high concentration.
These discrepancies may be due to differences in the pop-
ulations studied, in the index of antiarrhythmic activity used
or in the antiarrhythmic efficacy of oral and intravenous
propranolol. Eighty-six percent of our patients had ischemic
heart disease compared with only 16% of the patients studied
by Woosley et al. (4). Other studies (23) in patients with
ischemic heart disease support an antiarrhythmic efficacy
rate for propranolol similar to that seen in our study. Our
index for antiarrhythmic efficacy was suppression of in-
duction of ventricular tachycardia at electrophysiologic study,
whereas Woosley et al. (4) assessed antiarrhythmic efficacy
by suppression of isolated premature ventricular depolari-
zations and salvos of spontaneous nonsustained ventricular
tachycardia.
A final difference between our study and that of Woosley
et al. is that we assessed the antiarrhythmic efficacy of
intravenous propranolol while they used the oral prepara-
tion. Using a rabbit model, Raine and Vaughn-Williams
(24) showed that long-term propranolol treatment produced
repolarization changes that were absent during short-term
administration. Similarly Edvardsson and Olsson (25) re-
ported that, while short-term metoprolol treatment does not
affect repolarization, long-term treatment was associated
with prolongation of monophasic action potential duration
and refractoriness. To assess possible differences in the
antiarrhythmic efficacy of intravenous and oral propranolol,
five patients in our study who had responded to intravenous
propranolol were given oral propranolol therapy at matched
concentrations. Four of these five patients responded to oral
propranolol therapy, suggesting that the antiarrhythmic ef-
ficacies of intravenous and oral propranolol are similar but
not identical.
Possible limitations of study. Our results were obtained
in a selected group of patients and may not be applicable
to all patients with ventricular tachycardia. For example,
propranolol therapy is contraindicated for the majority of
patients with sustained ventricular tachycardia, ischemic heart
disease and advanced congestive heart failure. Even so,
eight of our patients had an ejection fraction of less than
35% and had no worsening of congestive heart failure with
propranolol. Another possible limitation to the general ap-
plicability of our data is that our patients had drug-resistant
ventricular tachycardia. It is possible that a higher (or lower)
proportion of patients with less drug-resistant arrhythmia
would respond to propranolol.
Conclusions. Our data suggest that propranolol is an
effective antiarrhythmic agent in 21% of patients with in-
ducible sustained ventricular tachycardia. Although high
concentration electrophysiologic effects of propranolol were
seen in this study and may have contributed to antiarrhyth-
mic efficacy in four patients, high concentrations were re-
quired for complete efficacy in only one individual. Because
most of the antiarrhythmic efficacy occurred at beta-adren-
oceptor blocking concentrations in patients with sinus tachy-
cardia at rest, we hypothesize that this efficacy is mediated
by blockade of catecholamine involvement in the genesis
of the tachyarrhythmias. Further investigations appear war-
ranted to assess the efficacy of propranolol in a broader
spectrum of patients with ventricular tachyarrhythmias in-
cluding further study of the mechanism of its cardioprotec-
tive effect in patients after myocardial infarction.
We thank Gregory Douglas and Brenda Mullinger for their help in preparing
the manuscript.
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